Home » Resources » Blog » Evaluating New 3-D Systems for Disease Modeling, Drug Validation, and Toxicology
Evaluating New 3-D Systems for Disease Modeling, Drug Validation, and Toxicology
Wednesday, May 30, 2018 - 16:31
Cell and tissue-based models are a necessary step in the workflow for toxicology testing, drug discovery*, and disease modeling. In recent years, the research and pharmaceutical industries have adopted more complex ex vivo and in vitro 3-D tissue models because of their better predictive power. The first part of this webinar discusses the history of cell- and tissue-based models systems for toxicology, drug validation, and disease modeling. Particular emphasis will be placed on culture methods and optimization of stem cell-based models and 3-D cell culture systems, including organoids. The second half of the webinar introduces MimEX™ Tissue Model Systems, a transformative culturing platform that builds upon the physiological and structural advancements of current organoid models by producing 3-D tissue with better accessibility and lower variability. The power of this platform will be demonstrated using stem cells isolated from human gastrointestinal tract (MimEX™ GI) as an example of various epithelial tissues that can be modeled using system.
History of cell and tissue model systems for toxicology and disease modeling
Troubleshooting variability in induced pluripotent stem cell-based models
Advantages and disadvantages of current 3-D culture systems
* Portions of MimEX Tissue Model Systems are covered by a license to intellectual property owned by, or licensed to, Multiclonal Therapeutics, Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right under these intellectual property rights to use this product for research purposes only. The purchase of this product does not include any right to use this product or components of this product for resale, for drug discovery intended for commercial gain, for the generation of cells or tissues intended for transplantation in human patients, or for any other commercial purposes, including without limitation, provision of services to a third party, generation of commercial databases, or as a diagnostic or therapeutic. Multiclonal Therapeutics, Inc., reserves all other rights under these rights. For information on purchasing a license to the intellectual property for uses other than in conjunction with this product or to use this product for purposes other than research, please contact Multiclonal Therapeutics, Inc. at email@example.com.